Plain-English translation of NCT07622316 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This research study is testing a combination treatment for autism spectrum disorder. The main medication being tested is called AdiaVita, which is made from stem cells and other healing compounds from umbilical cord blood. Researchers want to see if giving AdiaVita along with (a natural substance that supports the body) can help improve autism-related symptoms better than alone.
Currently, there are no proven medical treatments that can change the core features of autism spectrum disorder. This study exists to explore whether this medication might offer a new treatment option, building on earlier research suggesting that stem cell products may be safe and helpful for children with autism.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to receive either the new medication plus , or alone (with placebo infusions). Over 12 months, you'll visit the clinic monthly for intravenous infusions during the first three months, complete autism symptom evaluations, and continue using a spray twice daily at home. Your parent or guardian will track any changes in your abilities and behavior using a checklist, and the research team will monitor your health and safety throughout.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States